Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma

The development of BRAF and MEK inhibitors (BRAFi/MEKi) has led to major advances in melanoma treatment. However, the emergence of resistance mechanisms limits the benefit duration and a complete response occurs in less than 20% of patients receiving BRAFi ± MEKi. In this study, we evaluated the imp...

詳細記述

保存先:
書誌詳細
出版年:Transl Oncol
主要な著者: Reger de Moura, Coralie, Vercellino, Laetitia, Jouenne, Fanélie, Baroudjian, Barouyr, Sadoux, Aurélie, Louveau, Baptiste, Delyon, Julie, Serror, Kevin, Goldwirt, Lauriane, Merlet, Pascal, Bouquet, Fanny, Battistella, Maxime, Lebbé, Céleste, Mourah, Samia
フォーマット: Artigo
言語:Inglês
出版事項: Neoplasia Press 2019
主題:
Original article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6931208/
https://ncbi.nlm.nih.gov/pubmed/31874374
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2019.10.003
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料